Analyst Reco. NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
13.04 ^USD	-8.36%		-4.61%	+0.85%

Mar. 02	Novocure Announces Optune Lua®? Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer	CI
Mar. 02	Novocure Says It Receives Japan Reimbursement Approval For Optune Lua	MT

Analyst Reco.

25-07-25	NovoCure Shares Fall After Wells Fargo Downgrade	MT
25-07-25	Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $14.50 From $40	MT
25-07-24	Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating	MT
25-07-08	Ladenburg Thalmann Initiates NovoCure at Buy With $30 Price Target	MT
24-12-02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
24-12-02	Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	MT
24-12-02	Evercore ISI Upgrades NovoCure to Outperform	MT
24-10-16	HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	MT
24-06-04	Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating	MT
24-04-10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT
24-04-03	Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	MT
24-02-23	Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	MT
23-10-26	Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	MT
23-08-29	Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	MT
23-08-28	HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	MT
23-08-28	Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	MT
23-08-28	Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	MT
23-08-08	Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	MT
23-08-04	SVB Securities Initiates NovoCure at Outperform With $51 Price Target	MT
23-07-31	Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	MT
23-06-07	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT
23-06-07	Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	MT
23-06-07	Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	MT
23-05-16	Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $104 From $70	MT